A novel EGFR mutation in exon 19 showed stable disease after TKI treatment

Journal of Thoracic Oncology

Volumn 7, Issue 8, 2012, Pages

  Van Der Wekken, Anthonie J ^a   Stigt, Jos A ^a   A'T Hart, Nils ^a  

^a ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EXON; FEMALE; GENE MUTATION; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG CANCER; POINT MUTATION; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

EID: 84863814882     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31825ccae8     Document Type: Letter

References (2)

1. Yatabe Y, Pao W, Jett JR. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol 2012;7:775-776.
2. De Pas T, Toffalorio F, Manzotti M, et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011;6:1895-1901.